Stay updated with breaking news from Identifying Myocarditis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNT
Cases of myocarditis – an inflammation of the heart muscle – following a third dose of the Pfizer vaccine are rare and typically mild, research from Israel shows.
A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association's flagship journal Circulation.
The risk of developing myocarditis among males ages 16 to 19 years are about one in 15,000 after the third dose of the Pfizer-BioNTech Covid-19 vaccine, however the cases are rare and mild, according to a new research conducted in ...
Before the Covid pandemic, it was estimated that approximately 10 to 20 people per 100,000 were diagnosed with myocarditis each year, according to the American Heart Association (AHA).